Redwood, Cytisine, and the Next Generation of Nicotine Free Cessation
Share
For more than 40 years, the smoking cessation market has relied on the same basic idea: replace nicotine with more nicotine through gum, patches, or lozenges, and hope the user eventually quits. That approach has helped some people, but it has not solved the larger problem. Many smokers and vapers are not looking for another nicotine product. They are looking for a realistic way to move beyond nicotine altogether.
That is where Redwood Scientific Technologies is focused.
Redwood’s approach is built around 2 important ideas. First, the company is developing nicotine free platforms that use cytisine, a naturally occurring botanical alkaloid that has been studied for decades as a smoking cessation agent. Second, Redwood is designing the user experience around the way smoking and vaping actually work in daily life: taste, ritual, craving, habit, and oral fixation.
That combination is what makes the Redwood strategy different.
Smoking is not only a chemical dependency. It is also a sensory and behavioral routine. Smokers become attached to the hand to mouth pattern, the flavor profile, the moment of use, the break in the day, and the physical sensation of doing something familiar. Vapers experience a similar pattern through flavor, repetition, device use, and frequent craving response. Any serious next generation cessation product must respect that reality.
Redwood’s TBX FREE and TBX VAPE FREE platforms are designed around that insight. The objective is not simply to remove nicotine and ignore the user experience. The objective is to pair a nicotine free active ingredient strategy with a sensory experience that feels familiar, satisfying, and easy to integrate into real world behavior. That means attention to flavor profiling, mouth feel, convenience, portability, and the oral fixation component that many traditional cessation tools fail to address.
This is why oral thin film delivery matters. A strip is discreet, portable, simple to use, and aligned with modern consumer behavior. It does not require chewing, water, a patch, a device, or a prescription. It can fit naturally into daily routines, which is critical because addiction is often triggered by routine moments: driving, stress, work breaks, social settings, and the first craving of the day.
The public health need remains enormous. The CDC states that “Cigarette smoking remains the leading cause of preventable disease and death in the United States.”[1] The CDC also reports that cigarette smoking “kills more than 480,000 Americans each year.”[1] Vaping has expanded the problem. The CDC states that “Most e-cigarettes contain nicotine, which is highly addictive,” and also reports that “E-cigarettes are the most commonly used tobacco product among U.S. youth.”[2]
That is the market opening Redwood is pursuing.
The company is not trying to build another nicotine replacement product. It is advancing a nicotine free platform designed to address both sides of the problem: the biological addiction pathway and the sensory behavioral experience that keeps users trapped in the cycle.
The larger idea is simple.
If nicotine is the problem, the next generation of cessation should not be built around more nicotine. It should be built around helping people move beyond it.
Sources and References
[1] U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html
[2] U.S. Centers for Disease Control and Prevention
https://www.cdc.gov/tobacco/e-cigarettes/youth.html
About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.
Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.